Answers are grounded in this paper and cite their sources.
Ruxolitinib cream is licensed for the treatment of non‐segmental vitiligo with facial involvement in adolescents (≥12 years old) and adults. This article summarises its mechanism of action, the clinical trial evidence of efficacy and its place in therapy.
No takes yet. Share an insight, caveat, or question.
Steve Chaplin (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: